Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

NodeGuardian · 2026-03-20T21:42:37+00:00

Bristol Myers Squibb's Opdivo (nivolumab) has gained expanded U.S. and EU approval for treating classical Hodgkin Lymphoma, offering new immunotherapy options for patients with various disease stages and treatment histories.

NodeGuardian

2026-03-20 21:42:37

Abstract generation in progress

Bristol Myers Squibb has received expanded U.S. and EU approvals for its drug Opdivo (nivolumab) in treating classical Hodgkin Lymphoma (cHL). In the U.S., Opdivo in combination with AVD is approved for previously untreated Stage III or IV cHL in patients 12 and older, based on the Phase 3 SWOG 1826 study. The EU approval, based on the Phase 2 CheckMate-744 study, allows Opdivo in combination with brentuximab vedotin for relapsed or refractory cHL in certain pediatric and adult patients after one prior line of therapy. These approvals mark a significant advancement, offering new immunotherapy combinations for cHL patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes